The latest Viracta Therapeutics stock prices, stock quotes, news, and VIRX history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines.VIRX 1.6 +0.1799 +12.68% : VIRACTA THERAPEUTICS, INC. - MSN Money. VIRX Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research. Aug 7, 2023 · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Viracta Therapeutics (VIRX) The Viracta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar2 days ago · Viracta Therapeutics, Inc. - Hold. Zacks' proprietary data indicates that Viracta Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the VIRX shares ... VRAX | Complete Virax Biolabs Group Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Discover historical prices for VIRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Viracta Therapeutics, Inc. stock was issued.The average Viracta Therapeutics stock price prediction forecasts a potential upside of 627.27% from the current VIRX share price of $1.32. What is VIRX's forecast return on assets (ROA) for 2023-2026? Sep 13, 2023 · Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar Investors will be thrilled if VIRX’s share price rises to $10.00, which is the median consensus price. At that level, VIRX’s share price would be -584.93% below current price. To see how Viracta Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: VIRX stock’s performance was 1.39% ...SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger ...Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Viracta Therapeutics Inc have a median target of 10.00, with a high estimate of 13.00 and a low estimate of 7.00. The ...You can view all of the due diligence checks on VIRX's stock page. Is VIRX stock overvalued? Investors. use a variety of different financial metrics, analyses, models, and charts to gauge VIRX's intrinsic value.Using relative valuations . metrics:VIRX; may be undervalued based on its P/B ratio of 1.26x, relative to Biotechnology industry P/B ...Viracta Therapeutics, Inc. (VIRX) Stock Price, News, Quote & History - Yahoo Finance +12.69(+0.09%) Russell 2000 -4.21(-0.23%) Viracta Therapeutics, Inc. (VIRX) NasdaqGS - NasdaqGS Delayed... VIRX Earnings Date and Information. Viracta Therapeutics last released its quarterly earnings results on August 14th, 2023. The reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. Viracta Therapeutics has generated ($1.38) earnings per share over the last year ( ($1.38) diluted earnings per share). Current and Historical Performance Performance for Vanguard Growth Index Investor on Yahoo Finance.Posted on August 06, 2023. After Binglong Vigrx finished Stock speaking, she couldn Price t help but Today hold her hand and left the biggest palace, and walked into a small palace shaped like a gourd at the back. A few drops of cold sweat emerged from the back of the gigantic bald head of the fairy artifact Enlarged Clitoris Looking Like Penis ...Mar. 27. MT. RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk. Nov. 11. MT. Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share. 2022. miami dade youth fairpogo sign in Mar. 27. MT. RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk. Nov. 11. MT. Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share. 2022.ABOUT US We are a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Our lead product candidate is Nana-val, an all-oral combination therapy of our proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is currently being evaluated in multiple ongoing clinical trials, including ...May 17, 2023 · Viracta Therapeutics Inc (VIRX) stock is trading at $1.60 as of 11:26 AM on Wednesday, May 17, a rise of $0.35, or 28.11% from the previous closing price of $1.25. The stock has traded between $1.25 and $1.61 so far today. Volume today is high. See Viracta Therapeutics, Inc. (VIRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Sep 13, 2023 · Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar 2 days ago · Viracta Therapeutics, Inc. - Hold. Zacks' proprietary data indicates that Viracta Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the VIRX shares ... Vanguard Growth Index provides a market-cap-weighted portfolio of the largest and fastest-growing companies in the U.S. market. Concentration presents some risks, but its low turnover, tight ...Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days. SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pa... 5 months ago - GlobeNewsWire.Webull Financial LLC is a member of the Financial Industry Regulatory Authority , Securities Investor Protection Corporation , The New York Stock Exchange , NASDAQ and Cboe EDGX Exchange, Inc . Webull Financial LLC is a member of SIPC, which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash).Feb 24, 2021 · SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger ... Investors will be thrilled if VIRX’s share price rises to $10.00, which is the median consensus price. At that level, VIRX’s share price would be -584.93% below current price. To see how Viracta Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: VIRX stock’s performance was 1.39% ...Jul 5, 2021 · VIRX : Viracta Therapeutics stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical Analysis Mission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track short interest in stocks, and gain from the advantages of this powerful market data. Saturday September 2, 2023. 20 Min Delayed.Zhang backs up his bullish stance with an Outperform (i.e. Buy) rating on VIRX stock, while his $7 price target suggests a robust 462% upside for the coming year. flex time manager Complete Viracta Therapeutics Inc. stock information by Barron's. View real-time VIRX stock price and news, along with industry-best analysis. Viracta Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. VIRX updated stock price target summary.Viracta Therapeutics, Inc. (VIRX) Stock Price, News, Quote & History - Yahoo Finance +12.69(+0.09%) Russell 2000 -4.21(-0.23%) Viracta Therapeutics, Inc. (VIRX) NasdaqGS - NasdaqGS Delayed... Mar. 27. MT. RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk. Nov. 11. MT. Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share. 2022. Track Viracta Therapeutics Inc (VIRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe 73 rating InvestorsObserver gives to Viracta Therapeutics Inc stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, VIRX’s 73 overall rating means the stock scores better than 73 percent of all stocks.Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ... 2 days ago · Viracta Therapeutics, Inc. - Hold. Zacks' proprietary data indicates that Viracta Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the VIRX shares ... Find real-time VIRX - Viracta Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. VIRX - Viracta Therapeutics Inc Stock quote - CNNMoney.com Markets...Find real-time VIRX - Viracta Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. VIRX - Viracta Therapeutics Inc Stock quote - CNNMoney.com Markets... emperor of austria Sep 7, 2023 · Private equity firms account for 35% of Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) ownership, while institutions account for 28% nasdaq.com - September 6 at 2:48 PM: Daniel R. Chevallard Sells 3,655 Shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) Stock marketbeat.com - August 29 at 11:43 PM VIRX: Viracta Therapeutics Inc Stock Price Quote - NASDAQ GS - Bloomberg Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and...View the latest Viracta Therapeutics Inc. (VIRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Close price at the end of the last trading day (Friday, 8th Sep 2023) of the VIRX stock was $1.32. This is 1.49% less than the trading day before Thursday, 7th Sep 2023. During the day the stock fluctuated 18.79% from a day low at $1.17 to a day high of $1.39.What is the target price for Viracta Therapeutics (VIRX) stock? A. The latest price target for Viracta Therapeutics ( NASDAQ: VIRX) was reported by RBC Capital on Tuesday, August 15, 2023. The ... VIRX: Viracta Therapeutics Inc Stock Price Quote - NASDAQ GS - Bloomberg Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and...Sep 6, 2023 · The latest Viracta Therapeutics stock prices, stock quotes, news, and VIRX history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines. Investor Relations. Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred ...Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Viracta Therapeutics (VIRX)The consensus price target hints at a 334.8% upside potential for Sunesis (VIRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate... VIRX : 1.4800 (+2.07%) Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma Zacks - Thu Sep 8, 2022. Viracta (VIRX) receives Orphan ...The Viracta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Jul 5, 2023 · Here's Why Assertio Holdings (ASRT) Stock is Up This Year 07/07/22-8:36AM EST Zacks. Other News for VIRX H.C. Wainwright Keeps Their Buy Rating on Viracta Therapeutics (VIRX) 07/05/23-8:35AM EST ... Stock market risk: The chance that stock prices overall will decline. Stock markets tend to move in cycles, with periods of rising stock prices and periods of falling stock prices. Investment style risk: The chance that returns from mid- and large-capitalization dividend-paying value stocks will trail returns from the overall stock market ...Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ... americhoice fcu What is the target price for Viracta Therapeutics (VIRX) stock? A. The latest price target for Viracta Therapeutics ( NASDAQ: VIRX) was reported by RBC Capital on Tuesday, August 15, 2023. The ... Essentially the fund is a passively managed index fund geared toward investors who want to take a passive approach to investing in U.S. large-cap growth stocks. As of August 15, 2023, the fund has ... Sep 6, 2023 · The latest Viracta Therapeutics stock prices, stock quotes, news, and VIRX history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines. change casing May 17, 2023 · Zhang backs up his bullish stance with an Outperform (i.e. Buy) rating on VIRX stock, while his $7 price target suggests a robust 462% upside for the coming year. Sep 7, 2023 · Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Stock Price Statistics. The stock price has decreased by -72.14% in the last 52 weeks. The beta is -0.17, so VIRX's price volatility has been lower than the market average.Find the latest Vanguard Growth Index Investor (VIGRX) stock quote, history, news and other vital information to help you with your stock trading and investing. These Healthcare stocks are trading higher: -Viracta Therapeutics Inc ( VIRX) stock is trading at $1.68, a gain of $0.43, or 34.82%, on high volume. Viracta Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy. -Bausch Health Companies Inc ( BHC) stock is trading ...Track VIRAX BIOLABS GROUP LIMITED (VRAX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsEssentially the fund is a passively managed index fund geared toward investors who want to take a passive approach to investing in U.S. large-cap growth stocks. As of August 15, 2023, the fund has ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Viracta Therapeutics stock is Buy based on the current 4 buy ratings for VIRX. The average twelve-month price prediction for Viracta Therapeutics is $9.50 with a high price target of $16.00 and a low price target of $5.00.Posted on August 06, 2023. After Binglong Vigrx finished Stock speaking, she couldn Price t help but Today hold her hand and left the biggest palace, and walked into a small palace shaped like a gourd at the back. A few drops of cold sweat emerged from the back of the gigantic bald head of the fairy artifact Enlarged Clitoris Looking Like Penis ... school status Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ... VIRX 1.6 +0.1799 +12.68% : VIRACTA THERAPEUTICS, INC. - MSN Money. VIRX Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research.VIRX is shorted 1,140% !!! VIRX is sitting in the exact same situation as GME was just a short while ago, with the difference being that VIRX only has a 100,000 share float. This stock could go up to the thousands, or tens of thousands per share, with only a little effort. Oh yeah, the shorts only have one day left to cover.Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ... kasa downtown austin Find real-time VIRX - Viracta Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. VIRX - Viracta Therapeutics Inc Stock quote - CNNMoney.com Markets...16:00 EDT VIRX Stock Quote Delayed 30 Minutes Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday. By William White, InvestorPlace Writer Jan 9, 2023Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ... turkey on the map SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX ), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the second quarter of 2023.Feb 24, 2021 · Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as of merger close The 76 rating InvestorsObserver gives to Viracta Therapeutics Inc ( VIRX) stock puts it near the top of the Healthcare sector. In addition to scoring higher than 93 percent of stocks in the Healthcare sector, VIRX’s 76 overall rating means the stock scores better than 76 of all stocks. VIRX has an Overall Score of 76.Sep 8, 2023 · Viracta Therapeutics stock was originally listed at a price of $8,190.00 in Sep 27, 2005. If you had invested in Viracta Therapeutics stock at $8,190.00, your return over the last 17 years would have been -99.98%, for an annualized return of -39.94% (not including any dividends or dividend reinvestments). 52 Week Low Date 05/08/23. Market Cap 50.318M. Shares Out 38.41M. 10 Day Average Volume 0.14M. Dividend -. Dividend Yield -. Beta 1.23. YTD % Change -10.27.The 76 rating InvestorsObserver gives to Viracta Therapeutics Inc ( VIRX) stock puts it near the top of the Healthcare sector. In addition to scoring higher than 93 percent of stocks in the Healthcare sector, VIRX’s 76 overall rating means the stock scores better than 76 of all stocks. VIRX has an Overall Score of 76.May 17, 2023 · Zhang backs up his bullish stance with an Outperform (i.e. Buy) rating on VIRX stock, while his $7 price target suggests a robust 462% upside for the coming year. Jul 5, 2023 · Here's Why Assertio Holdings (ASRT) Stock is Up This Year 07/07/22-8:36AM EST Zacks. Other News for VIRX H.C. Wainwright Keeps Their Buy Rating on Viracta Therapeutics (VIRX) 07/05/23-8:35AM EST ... Mar. 27. MT. RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk. Nov. 11. MT. Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share. 2022.Zhang backs up his bullish stance with an Outperform (i.e. Buy) rating on VIRX stock, while his $7 price target suggests a robust 462% upside for the coming year.Current and Historical Performance Performance for Vanguard Growth Index Investor on Yahoo Finance.VIRX 1.6 +0.1799 +12.68% : VIRACTA THERAPEUTICS, INC. - MSN Money. VIRX Nasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Biotechnology & Medical Research. capt hirams resort Mar. 27. MT. RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk. Nov. 11. MT. Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share. 2022. A high-level overview of Viracta Therapeutics, Inc. (VIRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for VIRX stock stock is $9.60, which predicts an increase of 557.53%. The lowest target is $5.00 and the highest is $16. On average, analysts rate VIRX stock stock as a strong buy.Track VIRAX BIOLABS GROUP LIMITED (VRAX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVIRX: Viracta Therapeutics broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.Viracta Therapeutics Inc (VIRX) stock is trading at $1.60 as of 11:26 AM on Wednesday, May 17, a rise of $0.35, or 28.11% from the previous closing price of $1.25. The stock has traded between $1.25 and $1.61 so far today. Volume today is high.Jan 9, 2023 · 16:00 EDT VIRX Stock Quote Delayed 30 Minutes Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday. By William White, InvestorPlace Writer Jan 9, 2023 Mar. 27. MT. RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk. Nov. 11. MT. Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share. 2022. paper football SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger ...Viracta Therapeutics, Inc. Common Stock. P/E & PEG Ratios. page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the ...Aug 6, 2023 · Posted on August 06, 2023. After Binglong Vigrx finished Stock speaking, she couldn Price t help but Today hold her hand and left the biggest palace, and walked into a small palace shaped like a gourd at the back. A few drops of cold sweat emerged from the back of the gigantic bald head of the fairy artifact Enlarged Clitoris Looking Like Penis ... VIRX stock returns are also predicted based on historical data. According to our research, VIRX stock is a bad long-term investment. VIRX share price has been in a bear cycle for the past year.A high-level overview of Vanguard Growth Index Fund Investor Shares (VIGRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.VIRX is shorted 1,140% !!! VIRX is sitting in the exact same situation as GME was just a short while ago, with the difference being that VIRX only has a 100,000 share float. This stock could go up to the thousands, or tens of thousands per share, with only a little effort. Oh yeah, the shorts only have one day left to cover. Viracta Therapeutics Inc. advanced stock charts by MarketWatch. View VIRX historial stock data and compare to other stocks and exchanges. SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX ), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the second quarter of 2023. Sep 9, 2023 · VIRX: Viracta Therapeutics Inc Stock Price Quote - NASDAQ GS - Bloomberg Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and... Feb 24, 2021 · SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger ... Webull Financial LLC is a member of the Financial Industry Regulatory Authority , Securities Investor Protection Corporation , The New York Stock Exchange , NASDAQ and Cboe EDGX Exchange, Inc . Webull Financial LLC is a member of SIPC, which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash).Close price at the end of the last trading day (Friday, 8th Sep 2023) of the VIRX stock was $1.32. This is 1.49% less than the trading day before Thursday, 7th Sep 2023. During the day the stock fluctuated 18.79% from a day low at $1.17 to a day high of $1.39.VIGRX-Vanguard Growth Index Fund Investor Shares | Vanguard. Open an account. To see the profile for a specific Vanguard mutual fund, ETF, or 529 portfolio, browse a list of all: Vanguard mutual funds | Vanguard ETFs® | Vanguard 529 portfolios. Check out our FundAccess.Find real-time VIRX - Viracta Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. VIRX - Viracta Therapeutics Inc Stock quote - CNNMoney.com Markets...Essentially the fund is a passively managed index fund geared toward investors who want to take a passive approach to investing in U.S. large-cap growth stocks. As of August 15, 2023, the fund has ...SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX ), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the second quarter of 2023. Posted on August 06, 2023. After Binglong Vigrx finished Stock speaking, she couldn Price t help but Today hold her hand and left the biggest palace, and walked into a small palace shaped like a gourd at the back. A few drops of cold sweat emerged from the back of the gigantic bald head of the fairy artifact Enlarged Clitoris Looking Like Penis ... dfw map Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers barVIGRX-Vanguard Growth Index Fund Investor Shares | Vanguard. Open an account. To see the profile for a specific Vanguard mutual fund, ETF, or 529 portfolio, browse a list of all: Vanguard mutual funds | Vanguard ETFs® | Vanguard 529 portfolios. Check out our FundAccess. Jan 31, 2023 · Stock market risk: The chance that stock prices overall will decline. Stock markets tend to move in cycles, with periods of rising stock prices and periods of falling stock prices. Investment style risk: The chance that returns from mid- and large-capitalization dividend-paying value stocks will trail returns from the overall stock market ... Viracta Therapeutics, Inc. Common Stock (VIRX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the... wcsg The Viracta Therapeutics, Inc. stock price fell by -2.08% on the last day (Wednesday, 6th Sep 2023) from $1.44 to $1.41. During the last trading day the stock fluctuated 7.75% from a day low at $1.36 to a day high of $1.46. The price has risen in 6 of the last 10 days and is up by 7.63% over the past 2 weeks.4 Wall Street analysts have issued twelve-month target prices for Viracta Therapeutics' stock. Their VIRX share price forecasts range from $5.00 to $16.00. On average, they expect the company's share price to reach $9.50 in the next year. This suggests a possible upside of 619.7% from the stock's current price.VIRX is shorted 1,140% !!! VIRX is sitting in the exact same situation as GME was just a short while ago, with the difference being that VIRX only has a 100,000 share float. This stock could go up to the thousands, or tens of thousands per share, with only a little effort. Oh yeah, the shorts only have one day left to cover. Posted on August 06, 2023. After Binglong Vigrx finished Stock speaking, she couldn Price t help but Today hold her hand and left the biggest palace, and walked into a small palace shaped like a gourd at the back. A few drops of cold sweat emerged from the back of the gigantic bald head of the fairy artifact Enlarged Clitoris Looking Like Penis ...See Viracta Therapeutics, Inc. (VIRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.9:12a Sirius XM upgraded to hold from sell at Deutsche Bank ; 9:11a AMD stock price target raised to $145 from $108 at Benchmark View Top Holdings and Key Holding Information for Vanguard Growth Index Investor (VIGRX). VIRX stock returns are also predicted based on historical data. According to our research, VIRX stock is a bad long-term investment. VIRX share price has been in a bear cycle for the past year.Feb 8, 2022 · (See VIRX stock analysis on TipRanks) Pear Therapeutics (PEAR) The next penny stock we’re looking at is an interesting one. Pear Therapeutics is a clinical- and commercial-stage company, working ... a u s t Aug 7, 2023 · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Viracta Therapeutics (VIRX) Jul 5, 2023 · Here's Why Assertio Holdings (ASRT) Stock is Up This Year 07/07/22-8:36AM EST Zacks. Other News for VIRX H.C. Wainwright Keeps Their Buy Rating on Viracta Therapeutics (VIRX) 07/05/23-8:35AM EST ... Vanguard Growth Index provides a market-cap-weighted portfolio of the largest and fastest-growing companies in the U.S. market. Concentration presents some risks, but its low turnover, tight ...VIRX support price is $1.36 and resistance is $1.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIRX stock will trade within this expected range on the day.According to the issued ratings of 4 analysts in the last year, the consensus rating for Viracta Therapeutics stock is Buy based on the current 4 buy ratings for VIRX. The average twelve-month price prediction for Viracta Therapeutics is $9.50 with a high price target of $16.00 and a low price target of $5.00. Viracta Therapeutics Announces New Employment Inducement Grant. SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the ... henry doorly zoo omaha Mar 8, 2021 · Viracta Therapeutics Stock Chart and Share Price Forecast, Short-Term "VIRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Viracta Therapeutics Inc (VIRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 VIRX Earnings Date and Information. Viracta Therapeutics last released its quarterly earnings results on August 14th, 2023. The reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. Viracta Therapeutics has generated ($1.38) earnings per share over the last year ( ($1.38) diluted earnings per share).Current and Historical Performance Performance for Vanguard Growth Index Investor on Yahoo Finance. copiar What is the target price for Viracta Therapeutics (VIRX) stock? A. The latest price target for Viracta Therapeutics ( NASDAQ: VIRX) was reported by RBC Capital on Tuesday, August 15, 2023. The ... These Healthcare stocks are trading higher: -Viracta Therapeutics Inc ( VIRX) stock is trading at $1.68, a gain of $0.43, or 34.82%, on high volume. Viracta Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy. -Bausch Health Companies Inc ( BHC) stock is trading ...SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX ), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the second quarter of 2023. VIGRX-Vanguard Growth Index Fund Investor Shares | Vanguard. Open an account. To see the profile for a specific Vanguard mutual fund, ETF, or 529 portfolio, browse a list of all: Vanguard mutual funds | Vanguard ETFs® | Vanguard 529 portfolios. Check out our FundAccess. tise Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Viracta Therapeutics (VIRX)Sep 13, 2023 · Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar Viracta Therapeutics, Inc. Common Stock. P/E & PEG Ratios. page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the ... Jul 5, 2021 · VIRX : Viracta Therapeutics stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical Analysis Find the latest Vanguard Growth Index Investor (VIGRX) stock quote, history, news and other vital information to help you with your stock trading and investing.What this means: Viracta Therapeutics Inc (VIRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.The 73 rating InvestorsObserver gives to Viracta Therapeutics Inc stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, VIRX’s 73 overall rating means the stock scores better than 73 percent of all stocks.The average Viracta Therapeutics stock price prediction forecasts a potential upside of 627.27% from the current VIRX share price of $1.32. What is VIRX's forecast return on assets (ROA) for 2023-2026? You can view all of the due diligence checks on VIRX's stock page. Is VIRX stock overvalued? Investors. use a variety of different financial metrics, analyses, models, and charts to gauge VIRX's intrinsic value.Using relative valuations . metrics:VIRX; may be undervalued based on its P/B ratio of 1.26x, relative to Biotechnology industry P/B ... insidehealth VRAX | Complete Virax Biolabs Group Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Discover historical prices for VIGRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Vanguard Growth Index Investor stock was issued.The latest Viracta Therapeutics stock prices, stock quotes, news, and VIRX history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines.Viracta Therapeutics Inc. analyst estimates, including VIRX earnings per share estimates and analyst recommendations. ... 4:33p Microsoft Corp. stock rises Friday, outperforms market lctx stock VIGRX-Vanguard Growth Index Fund Investor Shares | Vanguard. Open an account. To see the profile for a specific Vanguard mutual fund, ETF, or 529 portfolio, browse a list of all: Vanguard mutual funds | Vanguard ETFs® | Vanguard 529 portfolios. Check out our FundAccess. Aug 7, 2023 · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Viracta Therapeutics (VIRX) (See VIRX stock analysis on TipRanks) Pear Therapeutics (PEAR) The next penny stock we’re looking at is an interesting one. Pear Therapeutics is a clinical- and commercial-stage company, working ...Feb 24, 2021 · SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger ... 52 Week Low Date 05/08/23. Market Cap 50.318M. Shares Out 38.41M. 10 Day Average Volume 0.14M. Dividend -. Dividend Yield -. Beta 1.23. YTD % Change -10.27. farm life According to the issued ratings of 4 analysts in the last year, the consensus rating for Viracta Therapeutics stock is Buy based on the current 4 buy ratings for VIRX. The average twelve-month price prediction for Viracta Therapeutics is $9.50 with a high price target of $16.00 and a low price target of $5.00. ABOUT US We are a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Our lead product candidate is Nana-val, an all-oral combination therapy of our proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is currently being evaluated in multiple ongoing clinical trials, including ...Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as of merger closeMay 17, 2023 · Zhang backs up his bullish stance with an Outperform (i.e. Buy) rating on VIRX stock, while his $7 price target suggests a robust 462% upside for the coming year. View Top Holdings and Key Holding Information for Vanguard Growth Index Investor (VIGRX). Jan 31, 2023 · Stock market risk: The chance that stock prices overall will decline. Stock markets tend to move in cycles, with periods of rising stock prices and periods of falling stock prices. Investment style risk: The chance that returns from mid- and large-capitalization dividend-paying value stocks will trail returns from the overall stock market ... Nasdaq | VIRX U.S.: Nasdaq Viracta Therapeutics Inc. Watch list After Hours Last Updated: Sep 1, 2023 7:45 p.m. EDT Delayed quote $ 1.5100 0.05 3.42% After Hours Volume: 1 Advanced Charting... juwanna mann Sep 7, 2023 · Private equity firms account for 35% of Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) ownership, while institutions account for 28% nasdaq.com - September 6 at 2:48 PM: Daniel R. Chevallard Sells 3,655 Shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) Stock marketbeat.com - August 29 at 11:43 PM Stock Price Statistics. The stock price has decreased by -72.14% in the last 52 weeks. The beta is -0.17, so VIRX's price volatility has been lower than the market average.Home VIRX • NASDAQ Viracta Therapeutics Inc Follow Share $1.30 Sep 8, 8:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer search Compare to Celldex Therapeutics, Inc. $28.77 CLDX1.62% Bio Path Holdings...Here's Why Assertio Holdings (ASRT) Stock is Up This Year 07/07/22-8:36AM EST Zacks. Other News for VIRX H.C. Wainwright Keeps Their Buy Rating on Viracta Therapeutics (VIRX) 07/05/23-8:35AM EST ...Viracta Therapeutics Announces New Employment Inducement Grant. SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the ... lockly smart lock Viracta Therapeutics Inc. advanced stock charts by MarketWatch. View VIRX historial stock data and compare to other stocks and exchanges.See Viracta Therapeutics, Inc. (VIRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Zhang backs up his bullish stance with an Outperform (i.e. Buy) rating on VIRX stock, while his $7 price target suggests a robust 462% upside for the coming year.Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Viracta Therapeutics Inc have a median target of 10.00, with a high estimate of 13.00 and a low estimate of 7.00. The ...